Concepts (243)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Monoclonal Gammopathy of Undetermined Significance | 6 | 2023 | 33 | 4.380 |
Why?
|
| Multiple Myeloma | 10 | 2024 | 325 | 4.330 |
Why?
|
| Prostatic Neoplasms | 16 | 2022 | 339 | 3.030 |
Why?
|
| Lymphoma, Non-Hodgkin | 6 | 2022 | 50 | 2.010 |
Why?
|
| Biomarkers, Tumor | 6 | 2019 | 461 | 1.240 |
Why?
|
| Early Detection of Cancer | 6 | 2024 | 267 | 1.100 |
Why?
|
| SEER Program | 5 | 2024 | 66 | 1.000 |
Why?
|
| Aged | 37 | 2025 | 13423 | 0.970 |
Why?
|
| Diet | 5 | 2021 | 497 | 0.940 |
Why?
|
| Electronic Health Records | 5 | 2023 | 342 | 0.890 |
Why?
|
| Middle Aged | 34 | 2025 | 16339 | 0.800 |
Why?
|
| Precancerous Conditions | 1 | 2023 | 70 | 0.790 |
Why?
|
| Breast Neoplasms | 5 | 2025 | 1118 | 0.780 |
Why?
|
| Paraproteinemias | 1 | 2022 | 17 | 0.770 |
Why?
|
| United States | 23 | 2024 | 7431 | 0.760 |
Why?
|
| Prostate-Specific Antigen | 3 | 2022 | 66 | 0.750 |
Why?
|
| Colorectal Neoplasms | 3 | 2023 | 263 | 0.740 |
Why?
|
| Aged, 80 and over | 18 | 2025 | 5125 | 0.720 |
Why?
|
| Humans | 58 | 2025 | 59476 | 0.710 |
Why?
|
| Male | 38 | 2024 | 27794 | 0.700 |
Why?
|
| Healthcare Disparities | 2 | 2024 | 330 | 0.690 |
Why?
|
| International Classification of Diseases | 1 | 2021 | 131 | 0.690 |
Why?
|
| Cause of Death | 3 | 2020 | 210 | 0.680 |
Why?
|
| Case-Control Studies | 12 | 2022 | 1057 | 0.670 |
Why?
|
| Registries | 5 | 2025 | 804 | 0.650 |
Why?
|
| Adult | 26 | 2025 | 15704 | 0.630 |
Why?
|
| Disease Progression | 6 | 2023 | 1119 | 0.610 |
Why?
|
| Algorithms | 2 | 2021 | 979 | 0.580 |
Why?
|
| Hypertension | 1 | 2023 | 570 | 0.570 |
Why?
|
| Neoplasm Proteins | 1 | 2018 | 278 | 0.520 |
Why?
|
| Fatty Acids | 2 | 2018 | 191 | 0.500 |
Why?
|
| Risk Factors | 14 | 2022 | 4991 | 0.490 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2017 | 208 | 0.480 |
Why?
|
| Hodgkin Disease | 1 | 2015 | 55 | 0.470 |
Why?
|
| Female | 24 | 2025 | 30779 | 0.450 |
Why?
|
| Socioeconomic Factors | 4 | 2021 | 742 | 0.440 |
Why?
|
| HIV Seronegativity | 1 | 2013 | 18 | 0.430 |
Why?
|
| Population Health | 2 | 2023 | 15 | 0.400 |
Why?
|
| Cardiovascular Diseases | 1 | 2020 | 789 | 0.400 |
Why?
|
| Dietary Fats | 2 | 2017 | 173 | 0.400 |
Why?
|
| Comorbidity | 5 | 2022 | 1080 | 0.390 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 2 | 2024 | 5 | 0.380 |
Why?
|
| Risk Reduction Behavior | 1 | 2012 | 121 | 0.380 |
Why?
|
| Prospective Studies | 11 | 2020 | 3072 | 0.370 |
Why?
|
| Young Adult | 9 | 2025 | 4277 | 0.360 |
Why?
|
| Vitamin D | 1 | 2012 | 132 | 0.360 |
Why?
|
| Zinc | 1 | 2011 | 91 | 0.340 |
Why?
|
| Sweden | 4 | 2017 | 42 | 0.320 |
Why?
|
| Cytokines | 1 | 2013 | 912 | 0.320 |
Why?
|
| Tooth Loss | 2 | 2008 | 8 | 0.300 |
Why?
|
| Neoplasms | 4 | 2019 | 1233 | 0.290 |
Why?
|
| Fatty Acids, Omega-3 | 2 | 2022 | 36 | 0.290 |
Why?
|
| Mammography | 2 | 2022 | 271 | 0.290 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2014 | 440 | 0.280 |
Why?
|
| Mortality | 3 | 2019 | 155 | 0.280 |
Why?
|
| Cohort Studies | 7 | 2017 | 2377 | 0.280 |
Why?
|
| Mass Screening | 3 | 2024 | 649 | 0.270 |
Why?
|
| Follow-Up Studies | 8 | 2022 | 2341 | 0.270 |
Why?
|
| Endoribonucleases | 2 | 2013 | 53 | 0.270 |
Why?
|
| Fruit | 2 | 2015 | 104 | 0.260 |
Why?
|
| Neoplasm Staging | 6 | 2020 | 448 | 0.260 |
Why?
|
| Surveys and Questionnaires | 8 | 2024 | 2516 | 0.260 |
Why?
|
| HIV Infections | 1 | 2013 | 914 | 0.260 |
Why?
|
| Puerto Rico | 3 | 2024 | 134 | 0.260 |
Why?
|
| Massachusetts | 4 | 2024 | 2023 | 0.250 |
Why?
|
| Multimorbidity | 2 | 2023 | 43 | 0.250 |
Why?
|
| Health Services Research | 2 | 2017 | 266 | 0.240 |
Why?
|
| Databases, Factual | 3 | 2021 | 815 | 0.240 |
Why?
|
| Biomarkers | 3 | 2022 | 1306 | 0.240 |
Why?
|
| Age Factors | 4 | 2021 | 1504 | 0.230 |
Why?
|
| Adolescent | 6 | 2024 | 5854 | 0.220 |
Why?
|
| Behavioral Risk Factor Surveillance System | 2 | 2023 | 43 | 0.220 |
Why?
|
| Proportional Hazards Models | 6 | 2017 | 674 | 0.220 |
Why?
|
| Occult Blood | 1 | 2023 | 16 | 0.210 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2022 | 12 | 0.200 |
Why?
|
| Lymphoma, Follicular | 1 | 2022 | 16 | 0.200 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2022 | 39 | 0.200 |
Why?
|
| Cross-Sectional Studies | 4 | 2024 | 2383 | 0.190 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2022 | 65 | 0.190 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2020 | 30 | 0.190 |
Why?
|
| Smoking | 3 | 2021 | 826 | 0.180 |
Why?
|
| Clinical Trials as Topic | 1 | 2024 | 439 | 0.180 |
Why?
|
| Electronics | 1 | 2021 | 34 | 0.180 |
Why?
|
| Papillomavirus Vaccines | 1 | 2022 | 67 | 0.180 |
Why?
|
| Trans Fatty Acids | 1 | 2020 | 4 | 0.180 |
Why?
|
| Precision Medicine | 2 | 2019 | 102 | 0.180 |
Why?
|
| Erythrocyte Membrane | 1 | 2020 | 23 | 0.180 |
Why?
|
| Outpatients | 1 | 2022 | 137 | 0.180 |
Why?
|
| Observational Studies as Topic | 1 | 2021 | 55 | 0.180 |
Why?
|
| Multiple Chronic Conditions | 1 | 2021 | 37 | 0.180 |
Why?
|
| Pandemics | 2 | 2022 | 617 | 0.180 |
Why?
|
| Social Class | 1 | 2021 | 122 | 0.170 |
Why?
|
| Europe | 1 | 2021 | 182 | 0.170 |
Why?
|
| Papillomavirus Infections | 1 | 2022 | 120 | 0.170 |
Why?
|
| Kallikreins | 1 | 2020 | 8 | 0.170 |
Why?
|
| Hypersensitivity | 1 | 2021 | 62 | 0.170 |
Why?
|
| Antigens | 1 | 2021 | 146 | 0.170 |
Why?
|
| Survival Analysis | 2 | 2012 | 554 | 0.170 |
Why?
|
| C-Reactive Protein | 3 | 2014 | 159 | 0.170 |
Why?
|
| Disabled Persons | 1 | 2022 | 189 | 0.160 |
Why?
|
| Mutation, Missense | 1 | 2010 | 172 | 0.160 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2019 | 12 | 0.160 |
Why?
|
| Delivery of Health Care | 3 | 2019 | 413 | 0.160 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2024 | 725 | 0.160 |
Why?
|
| Models, Statistical | 1 | 2020 | 299 | 0.160 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2019 | 68 | 0.160 |
Why?
|
| Autoimmune Diseases | 1 | 2021 | 221 | 0.160 |
Why?
|
| Human papillomavirus 16 | 1 | 2008 | 17 | 0.160 |
Why?
|
| Prognosis | 3 | 2019 | 1598 | 0.150 |
Why?
|
| Hospitals | 1 | 2022 | 378 | 0.150 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 2018 | 15 | 0.150 |
Why?
|
| Medicare | 1 | 2023 | 601 | 0.150 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2023 | 454 | 0.150 |
Why?
|
| Incidence | 5 | 2025 | 1239 | 0.150 |
Why?
|
| Periodontal Diseases | 1 | 2008 | 17 | 0.150 |
Why?
|
| Periodontitis | 1 | 2008 | 15 | 0.150 |
Why?
|
| Ovarian Neoplasms | 1 | 2019 | 130 | 0.150 |
Why?
|
| Sex Factors | 1 | 2021 | 938 | 0.140 |
Why?
|
| Cancer Survivors | 1 | 2019 | 79 | 0.140 |
Why?
|
| Survival Rate | 2 | 2019 | 801 | 0.140 |
Why?
|
| Telemedicine | 1 | 2022 | 310 | 0.140 |
Why?
|
| Head and Neck Neoplasms | 1 | 2008 | 148 | 0.140 |
Why?
|
| Organizational Objectives | 1 | 2017 | 57 | 0.140 |
Why?
|
| Odds Ratio | 2 | 2018 | 748 | 0.140 |
Why?
|
| Dairy Products | 1 | 2017 | 15 | 0.140 |
Why?
|
| Lymphoma | 1 | 2017 | 99 | 0.140 |
Why?
|
| Health Personnel | 2 | 2013 | 342 | 0.130 |
Why?
|
| Milk | 1 | 2017 | 39 | 0.130 |
Why?
|
| Education | 1 | 2017 | 68 | 0.130 |
Why?
|
| Medical Oncology | 1 | 2017 | 57 | 0.130 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 1029 | 0.130 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2008 | 237 | 0.130 |
Why?
|
| Opioid-Related Disorders | 1 | 2023 | 457 | 0.130 |
Why?
|
| Homes for the Aged | 1 | 2018 | 157 | 0.130 |
Why?
|
| Cholesterol | 1 | 2017 | 253 | 0.130 |
Why?
|
| Inflammation | 2 | 2021 | 1099 | 0.130 |
Why?
|
| BRCA2 Protein | 1 | 2016 | 13 | 0.130 |
Why?
|
| Genomics | 1 | 2018 | 322 | 0.120 |
Why?
|
| Burkitt Lymphoma | 1 | 2016 | 57 | 0.120 |
Why?
|
| Connecticut | 1 | 2015 | 86 | 0.120 |
Why?
|
| Population Surveillance | 2 | 2016 | 195 | 0.120 |
Why?
|
| Meat | 1 | 2015 | 33 | 0.120 |
Why?
|
| Vegetables | 1 | 2015 | 66 | 0.120 |
Why?
|
| Vasectomy | 1 | 2014 | 1 | 0.120 |
Why?
|
| Antineoplastic Agents | 1 | 2019 | 628 | 0.110 |
Why?
|
| Herpesvirus 4, Human | 1 | 2015 | 178 | 0.110 |
Why?
|
| Emergency Service, Hospital | 1 | 2022 | 1021 | 0.110 |
Why?
|
| Veterans | 1 | 2021 | 728 | 0.110 |
Why?
|
| Life Style | 1 | 2015 | 299 | 0.110 |
Why?
|
| Feeding Behavior | 1 | 2015 | 254 | 0.110 |
Why?
|
| Time Factors | 3 | 2012 | 3619 | 0.110 |
Why?
|
| Homosexuality, Male | 1 | 2013 | 38 | 0.110 |
Why?
|
| Prevalence | 1 | 2017 | 1257 | 0.100 |
Why?
|
| Obesity | 1 | 2021 | 1168 | 0.100 |
Why?
|
| Cholestanetriol 26-Monooxygenase | 1 | 2012 | 3 | 0.100 |
Why?
|
| Vitamin D-Binding Protein | 1 | 2012 | 4 | 0.100 |
Why?
|
| 25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 1 | 2012 | 4 | 0.100 |
Why?
|
| Retinoid X Receptor alpha | 1 | 2012 | 6 | 0.100 |
Why?
|
| Vitamin D3 24-Hydroxylase | 1 | 2012 | 7 | 0.100 |
Why?
|
| Steroid Hydroxylases | 1 | 2012 | 9 | 0.100 |
Why?
|
| Genetic Association Studies | 1 | 2013 | 113 | 0.100 |
Why?
|
| Receptors, Calcitriol | 1 | 2012 | 33 | 0.100 |
Why?
|
| Nursing Homes | 1 | 2018 | 661 | 0.100 |
Why?
|
| Seasons | 1 | 2012 | 123 | 0.100 |
Why?
|
| Health Behavior | 1 | 2015 | 452 | 0.100 |
Why?
|
| Antioxidants | 1 | 2013 | 241 | 0.090 |
Why?
|
| Body Mass Index | 1 | 2015 | 832 | 0.090 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2011 | 339 | 0.080 |
Why?
|
| Genotype | 3 | 2013 | 619 | 0.080 |
Why?
|
| California | 2 | 2020 | 161 | 0.080 |
Why?
|
| Gene Expression Profiling | 1 | 2012 | 720 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2012 | 677 | 0.080 |
Why?
|
| Cell Membrane | 2 | 2022 | 487 | 0.070 |
Why?
|
| National Cancer Institute (U.S.) | 2 | 2017 | 33 | 0.070 |
Why?
|
| Risk Assessment | 3 | 2020 | 1927 | 0.070 |
Why?
|
| RNA, Messenger | 1 | 2012 | 1469 | 0.070 |
Why?
|
| Interleukin-6 | 2 | 2013 | 309 | 0.060 |
Why?
|
| Logistic Models | 2 | 2018 | 1237 | 0.060 |
Why?
|
| Vietnam | 1 | 2025 | 165 | 0.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2019 | 402 | 0.060 |
Why?
|
| Trust | 1 | 2024 | 67 | 0.050 |
Why?
|
| Retrospective Studies | 3 | 2020 | 6085 | 0.050 |
Why?
|
| Genetic Testing | 1 | 2024 | 127 | 0.050 |
Why?
|
| Patient Participation | 1 | 2024 | 216 | 0.050 |
Why?
|
| Time-to-Treatment | 1 | 2022 | 98 | 0.050 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2022 | 127 | 0.050 |
Why?
|
| Life Tables | 1 | 2020 | 23 | 0.040 |
Why?
|
| Marital Status | 1 | 2020 | 43 | 0.040 |
Why?
|
| Genetic Variation | 2 | 2014 | 357 | 0.040 |
Why?
|
| Scandinavian and Nordic Countries | 1 | 2010 | 5 | 0.040 |
Why?
|
| Finland | 1 | 2010 | 19 | 0.040 |
Why?
|
| Michigan | 1 | 2020 | 41 | 0.040 |
Why?
|
| Regional Medical Programs | 1 | 2020 | 6 | 0.040 |
Why?
|
| Preventive Health Services | 1 | 2020 | 72 | 0.040 |
Why?
|
| Liquid Biopsy | 1 | 2019 | 4 | 0.040 |
Why?
|
| Health Plan Implementation | 1 | 2020 | 40 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2020 | 75 | 0.040 |
Why?
|
| Vaccination | 1 | 2022 | 334 | 0.040 |
Why?
|
| Advisory Committees | 1 | 2020 | 108 | 0.040 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2019 | 29 | 0.040 |
Why?
|
| Health Surveys | 1 | 2020 | 299 | 0.040 |
Why?
|
| Public Health Surveillance | 1 | 2019 | 28 | 0.040 |
Why?
|
| Colorado | 1 | 2019 | 19 | 0.040 |
Why?
|
| Washington | 1 | 2019 | 23 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2020 | 487 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 79 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2020 | 354 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2019 | 353 | 0.040 |
Why?
|
| Analgesics, Opioid | 1 | 2023 | 488 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2018 | 130 | 0.040 |
Why?
|
| Self Report | 1 | 2020 | 359 | 0.040 |
Why?
|
| Research | 1 | 2019 | 187 | 0.040 |
Why?
|
| Data Collection | 1 | 2019 | 373 | 0.040 |
Why?
|
| Guideline Adherence | 1 | 2020 | 296 | 0.040 |
Why?
|
| Disease Management | 1 | 2019 | 220 | 0.040 |
Why?
|
| Medication Adherence | 1 | 2020 | 241 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2018 | 299 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 1188 | 0.030 |
Why?
|
| Research Personnel | 1 | 2017 | 92 | 0.030 |
Why?
|
| Mentors | 1 | 2017 | 115 | 0.030 |
Why?
|
| Kenya | 1 | 2016 | 79 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2016 | 30 | 0.030 |
Why?
|
| Watchful Waiting | 1 | 2016 | 24 | 0.030 |
Why?
|
| Quality Improvement | 1 | 2020 | 418 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2016 | 162 | 0.030 |
Why?
|
| Research Design | 1 | 2018 | 556 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 396 | 0.030 |
Why?
|
| Biopsy | 1 | 2016 | 410 | 0.030 |
Why?
|
| Cytoplasm | 1 | 2016 | 271 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2016 | 851 | 0.030 |
Why?
|
| Risk | 1 | 2014 | 364 | 0.030 |
Why?
|
| Androgen Antagonists | 1 | 2013 | 20 | 0.030 |
Why?
|
| Prostate | 1 | 2013 | 65 | 0.030 |
Why?
|
| Prostatectomy | 1 | 2013 | 64 | 0.030 |
Why?
|
| Cell Nucleus | 1 | 2016 | 608 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2016 | 845 | 0.020 |
Why?
|
| Infant | 1 | 2016 | 1493 | 0.020 |
Why?
|
| Molecular Epidemiology | 1 | 2011 | 25 | 0.020 |
Why?
|
| Linkage Disequilibrium | 1 | 2011 | 46 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2016 | 1796 | 0.020 |
Why?
|
| Child | 1 | 2016 | 4205 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2013 | 5293 | 0.010 |
Why?
|
| Animals | 1 | 2017 | 19680 | 0.010 |
Why?
|